Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients
The liver plays a central role in the pharmacokinetics of drugs through drug metabolizing enzymes and transporters. Non-alcoholic steatohepatitis (NASH) causes disease-specific alterations to the absorption, distribution, metabolism, and excretion (ADME) processes, including a decrease in protein ex...
Main Authors: | Solène Marie, Kayla L. Frost, Raymond K. Hau, Lucy Martinez-Guerrero, Jailyn M. Izu, Cassandra M. Myers, Stephen H. Wright, Nathan J. Cherrington |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522003690 |
Similar Items
-
Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity
by: Joseph L. Jilek, et al.
Published: (2021-12-01) -
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
by: Mazen Noureddin, et al.
Published: (2020-10-01) -
Pharmacokinetics and metabolism in drug design /
by: 464017 Smith, Dennis A., et al.
Published: (2006) -
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01) -
Pharmacokinetic profiling in drug research : biological, physicochemical and computational strategies /
by: Lipophilicity Symposium (3rd : 2004 : Swiss Federal Institute of Technology), et al.
Published: (2006)